Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Completion of Operational Review
Company Will Prioritize Continued Development of Mirvetuximab Soravtansine and a Select Portfolio of Earlier-Stage Candidates Cash Runway Extended Through Readout of Mirvetuximab Soravtansine Pivotal Trial in Ovarian Cancer Conference Call to be Held at 8 a.m. ET Today WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer
Results to be Presented at 2019 ASCO Annual Meeting Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Platinum-Sensitive
View HTML
Toggle Summary ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer
Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass. --(BUSINESS WIRE)--May 15, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the United States Food and Drug Administration ( FDA )
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results
Encouraging Efficacy Signal Observed in Pre-Specified Subset of Patients in Phase 3 FORWARD I Study; Company to Meet with Regulators this Quarter to Discuss Potential Path Forward for Mirvetuximab Soravtansine Monotherapy FORWARD II Trial with Mirvetuximab Combinations Continues to Enroll, with
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 18, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer
Trial Did Not Meet Primary Endpoint of Progression-Free Survival Efficacy Signal Seen in High Folate Receptor Alpha Patients; Additional Analyses to be Conducted Favorable Tolerability Profile Confirmed Combination Regimens to be Evaluated as an Independent Path Forward to Support Registration in
View HTML
Toggle Summary ImmunoGen Announces Multiple Presentations at AACR Annual Meeting
Continued Innovation in ADCs Highlighted in Eleven Posters First-in-Class ADAM9-targeting ADC, IMGC936, Developed in Collaboration with MacroGenics , Demonstrates Preclinical Activity in Models of Non-Small Cell Lung, Gastric, and Colorectal Cancers Novel DARPin ® Drug Conjugate Platform Evaluated
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and 2018 Operating Results
Top-Line Data from Phase 3 FORWARD I Mirvetuximab Soravtansine Study on Track for First Half of 2019 Encouraging Clinical Data from Novel IGN Pipeline Highlighted in Two Oral Presentations at ASH 2018 Sale of Kadcyla ® Royalty Tail for $65 Million Further Strengthens Financial Position Conference
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 24, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at  8:00 a.m.
View HTML
Toggle Summary ImmunoGen Announces Sale of Residual Kadcyla Royalties
Company to Receive $65 Million Payment WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 8, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the sale of its residual rights to receive royalty payments on
View HTML